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394a Tuesday, March 8, 2011This suggests that chloroquine and NADH are competitive inhibitors for this
particular enzyme. In this study, molecular docking was used to determine
and explore potential binding of chloroquine to Plasmodium falciparum glyc-
eraldehyde-3-phosphate dehydrogenase (pfGAPDH), another glycolytic en-
zyme that shares a common cofactor with LDH. Automated docking using
Autodock 4.2 was employed to determine binding sites and binding energies
of chloroquine docked to monomeric and tetrameric forms of pfGAPDH
with and without the cofactor present.
Docking solutions for the monomer revealed two binding sites for chloroquine,
one of which was the cofactor binding pocket. In the absence of NADH, 61 %
of conformations with sufficiently low binding energy were located in the
NADH binding pocket (average binding energy of 5.943 5 0.085 kcal/
mol) with 31% in the secondary binding site (average binding energy of
4.937 5 0.025 kcal/mol). With the cofactor present, the secondary binding
pocket accounted for 100% of stable complexes with an average binding energy
of 4.8035 0.015 kcal/mol. With the tetramer, the most stable complexes
were found in a new hydrophobic pocket at the interface between the subunits
with 56% and 80% favorability in the absence and presence of cofactor,
respectively.
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Optimization of a BCL6 Inhibitor using the Site-Identification by Ligand
Competitive Saturation (SILCS)
Wenbo Yu, Alexander D. MacKerell, Jr.
Fragment-based drug design has developed significantly over the past ten years
and is now recognized as a successful method of lead compound generation and
optimization[1]. Computational approaches to fragment-based drug discovery
have the potential to dramatically mitigate the costs of experimental based ap-
proach. However, the majority of computational methods suffer from limited
representation of protein flexibility and solvation effects. Recently, a frag-
ment-based approach based on explicit solvent all-atom molecular dynamics
simulations (SILCS: Site Identification by Ligand Competitive Saturation)
was developed in our lab to overcome these drawbacks[2]. As a test case, we
applied this method to the BTB domain of BCL6 protein. Good agreements be-
tween calculated three-dimensional probability maps of fragment binding and
the X-ray structure of the BCL6 inhibitor 79-6[3] were found. In addition,
a more specific SILCS simulation was performed and several potential func-
tional group binding sites around the location of 79-6 were identified. Based
on the location of these functional groups, modifications of 79-6 were pro-
posed. Free energy perturbation (FEP) calculations, including FEP using the or-
thogonal space random walk (OSRW) approach[4], were applied to obtain
quantitative computational estimates of the relative free energy of binding as-
sociated with these modifications. Two FEP methods show consistent results
that the modified compound has higher binding affinity to BCL6 than parent
compound 79-6. This result indicates that the SILCS method has the ability
to qualitatively inform the optimization of small-molecule inhibitors.
[1] Schulz, M.; Hubbard, R. Curr. Opin. Pharmacol. 2009, 5, 615.
[2] Guvench, O.; MacKerell, A. D., Jr. PLoS Comput. Biol. 2009, 5, e1000435.
[3] Cerchietti, L. C.; Ghetu, A. F.; Zhu, X. and et al. Cancer Cell 2010, 17, 1.
[4] Zheng, L.; Chen, M.; Yang, W. Proc. Natl. Acad. Sci. U.S.A. 2008, 105,
20227.
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Exploring New Druggable Binding Sites of Platelet Integrin aIIbb3
Ana Negri, Sarasija Naini, Barry S. Coller, Marta Filizola.
The major ligand binding site of platelet integrin alphaIIbbeta3, an essential
receptor for hemostasis and thrombosis, lies between the head regions of its
alpha and beta subunits. The Arginine-Glycine-Aspartic Acid (RGD) cell at-
tachment sequence mediates the binding of several different adhesive plasma
proteins to integrin alphaIIbbeta3. This sequence binds to both alphaIIb and
beta3 residues in the ligand binding pocket, as well as to a divalent metal
ion contained in the beta3 subunit. We recently identified a novel alphaIIb-
beta3 antagonist (RUC-1) that binds exclusively to alphaIIb. In the present
study we searched for additional new druggable binding sites of the integrin
alphaIIbbeta3 headpiece along the conformational transition between its
closed and open (swung-out) conformations. Specifically, we considered ten
different alphaIIbbeta3 conformations resulting from a linear interpolation be-
tween the two extreme conformations of alphaIIbbeta3, and relaxed them by
multi-nanosecond molecular dynamics simulations. Each trajectory was clus-
tered by root mean square deviation over the protein Calpha atoms, and each
cluster medoid was used as an input to a recent energy-based mapping algo-
rithm (FTMAP) that searches an entire protein surface for consensus binding
regions for a number of small organic probe molecules. Our results reveal
new pockets at the beginning of the conformational transition whose structural
information might be used as the basis for rational drug design of novel ther-
apeutics targeting integrin alphaIIbbeta3.2130-Pos Board B116
A New Class of Lipidic Immunomodulators that Activate TLR-Dependent
Cascades and Cytokine Secretion
Caroline Lonez, Michel Vandenbranden, Jean-Marie Ruysschaert.
Cationic lipids are positively charged amphiphilic molecules which, for most
of them, form positively charged liposomes, sometimes in combination with
a neutral helper lipid. Such liposomes are mainly used as efficient DNA,
RNA or protein carriers for gene therapy or immunization trials. Over the
past decade, significant progress has been made in the understanding of the
cellular pathways and mechanisms involved in lipoplex-mediated gene trans-
fection (1) but the interaction of cationic lipids with cell components and the
consequences of such an interaction on cell physiology remains poorly de-
scribed. Recently, trying to explain the immunoadjuvant properties (2) of a cat-
ionic lipid discovered in our group (N-t-butyl-N’-tetradecyl-3-
tetradecylamino-propionamidine-diC14-amidine), we identified its agonistic
interaction with the Toll-like receptor 4 (TLR4), the natural sensor of LPS
(the bacterial lipopolysaccharide). This activation seems specific of the shape
and characteristics of the molecule since increasing the length of the hydrocar-
bon chains by 2 methyl groups suppresses its activity. This cationic lipid has
only limited features in common with LPS species from different bacterial or-
igin such as short hydrocarbon chains and the presence of a polar headgroup.
However, the number of chains (2 versus generally 6 to 7) and the polar head-
group (small alkylated cationic amidinium group versus the bulky polar an-
ionic headgroup of LPS) make the two molecules look very different but
surprisingly such dissimilar structures are capable of activating the same re-
ceptor(3). As compared with other adjuvants being currently developed, the
chemistry of amidine derivatives is rather simple, allowing the quick develop-
ment and screening of new derivatives.
1- Mol Ther. (2005) 11(3):336-47
2- Mol Ther. (2005) 11 (6), 960-968
3- Prog Lipid Res. (2008) 47(5):340-7
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Local Protein Surface Patch Method for Protein-Ligand Binding
Prediction
Lee Sael, Daisuke Kihara.
Characterizing the protein structures of an unknown function is an important
task in bioinformatics. Function of a protein, specifically, the type of ligand
that bind to a protein, can be predicted by finding similar local surface re-
gions of known proteins. Unlike existing methods that compare the global
characteristics of a protein fold, we propose a local surface-based approach
which can find functional similarity between non-homologous proteins. In
the proposed pocket comparison method, the pockets are segmented to sur-
face patches, which are then compared using a modified weighted bipartite
matching algorithm. The 3D Zernike descriptors, which have been found to
be successful in representing protein global surface properties (Sael L, Li
B et al. Proteins, 2008; Sael L, La D et al. Proteins, 2008) and global pockets
shape comparison (Chikhi R et al. Proteins, 2010), are used to encode the
geometric and physicochemical properties of the surface patches. By repre-
senting a pocket by a set of local patches, local similarity of binding pockets
can be captured. This is effective when pocket shapes are slightly different
due to flexibility of ligand molecules. The binding ligand prediction perfor-
mance was evaluated on a data set of 100 non-homologous proteins that
bind to either one of nine types of ligands. 84.0% of the binding ligands
were predicted correctly within the top three scores using the shape and
pocket size information, which is better than the previous method which
uses the surface of whole pocket. The performance was further improved
to 87.0% when surface properties, i.e. electrostatic potential and hydrophobic-
ity, were added. Overall, we show that proposed method is powerful in pre-
dicting the type of ligand a protein binds even in the absence of homologous
proteins in the database.
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A Novel Method for Guiding Protein-Ligand Docking with QSAR-Derived
Pharmacophore Maps
Sam DeLuca, Jens Meiler.
Currently, QSAR and computational ligand docking studies are valuable but in-
dependently used tools for drug design. Data from Pharmacophore maps pro-
duced by tools such as COMFA are typically compared to the results of
docking simulations by hand in a qualitative manner. RosettaLigand has
been previously successful at predicting binding poses with high resolution res-
olution (Kaufmann, et. al, Proteins, 2009). We are developing RosettaHTS, an
extension to RosettaLigand which will integrate these two methods by using
information from QSAR derived pharmacophore maps to guide the low resolu-
tion phase of ligand docking. Pharmacophore maps are generated using
